These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38563128)

  • 1. New knowledge on anti-IgLON5 disease.
    Gaig C; Sabater L
    Curr Opin Neurol; 2024 Jun; 37(3):316-321. PubMed ID: 38563128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular Motor Abnormalities in Anti-IgLON5 Disease.
    Macher S; Milenkovic I; Zrzavy T; Höftberger R; Seidel S; Berger-Sieczkowski E; Berger T; Rommer PS; Wiest G
    Front Immunol; 2021; 12():753856. PubMed ID: 34659261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothalamic-Bulbar MRI Hyperintensity in Anti-IgLON5 Disease with Serum-Restricted Antibodies: A Case Report and Systematic Review of Literature.
    Tagliapietra M; Frasson E; Cardellini D; Mariotto S; Ferrari S; Zanusso G; Plebani M; Monaco S
    J Alzheimers Dis; 2021; 79(2):683-691. PubMed ID: 33337376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropathological criteria of anti-IgLON5-related tauopathy.
    Gelpi E; Höftberger R; Graus F; Ling H; Holton JL; Dawson T; Popovic M; Pretnar-Oblak J; Högl B; Schmutzhard E; Poewe W; Ricken G; Santamaria J; Dalmau J; Budka H; Revesz T; Kovacs GG
    Acta Neuropathol; 2016 Oct; 132(4):531-43. PubMed ID: 27358064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease.
    Berger-Sieczkowski E; Endmayr V; Haider C; Ricken G; Jauk P; Macher S; Pirker W; Högl B; Heidbreder A; Schnider P; Bradley-Zechmeister E; Mariotto S; Koneczny I; Reinecke R; Kasprian G; Weber C; Bergmann M; Milenkovic I; Berger T; Gaig C; Sabater L; Graus F; Gelpi E; Höftberger R
    Acta Neuropathol; 2023 Oct; 146(4):631-645. PubMed ID: 37646790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered ioflupane single-photon emission computed tomography in anti-IgLON5 disease: A new case mimicking probable progressive supranuclear palsy and review of the literature.
    González-Ávila C; Casado L; Muro García I; Villacieros-Álvarez J; Vivancos J; Quintas S
    Eur J Neurol; 2021 Apr; 28(4):1392-1395. PubMed ID: 33175431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration.
    Landa J; Gaig C; Plagumà J; Saiz A; Antonell A; Sanchez-Valle R; Dalmau J; Graus F; Sabater L
    Ann Neurol; 2020 Nov; 88(5):1023-1027. PubMed ID: 32740999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome.
    Sabater L; Planagumà J; Dalmau J; Graus F
    J Neuroinflammation; 2016 Sep; 13(1):226. PubMed ID: 27586161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease.
    Gaig C; Compta Y
    Curr Opin Neurol; 2019 Jun; 32(3):493-499. PubMed ID: 30694925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study.
    Sabater L; Gaig C; Gelpi E; Bataller L; Lewerenz J; Torres-Vega E; Contreras A; Giometto B; Compta Y; Embid C; Vilaseca I; Iranzo A; Santamaría J; Dalmau J; Graus F
    Lancet Neurol; 2014 Jun; 13(6):575-86. PubMed ID: 24703753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IgLON5 Disease: A New Bulbar-Onset Motor Neuron Mimic Syndrome.
    Werner J; Jelcic I; Schwarz EI; Probst-Müller E; Nilsson J; Schwizer B; Bloch KE; Lutterotti A; Jung HH; Schreiner B
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33531378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease.
    Grüter T; Möllers FE; Tietz A; Dargvainiene J; Melzer N; Heidbreder A; Strippel C; Kraft A; Höftberger R; Schöberl F; Thaler FS; Wickel J; Chung HY; Seifert F; Tschernatsch M; Nagel M; Lewerenz J; Jarius S; Wildemann BC; de Azevedo L; Heidenreich F; Heusgen R; Hofstadt-van Oy U; Linsa A; Maaß JJ; Menge T; Ringelstein M; Pedrosa DJ; Schill J; Seifert-Held T; Seitz C; Tonner S; Urbanek C; Zittel S; Markewitz R; Korporal-Kuhnke M; Schmitter T; Finke C; Brüggemann N; Bien CI; Kleiter I; Gold R; Wandinger KP; Kuhlenbäumer G; Leypoldt F; Ayzenberg I;
    Brain; 2023 Feb; 146(2):600-611. PubMed ID: 35259208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurodegeneration Induced by Anti-IgLON5 Antibodies Studied in Induced Pluripotent Stem Cell-Derived Human Neurons.
    Ryding M; Gamre M; Nissen MS; Nilsson AC; Okarmus J; Poulsen AAE; Meyer M; Blaabjerg M
    Cells; 2021 Apr; 10(4):. PubMed ID: 33917676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IGLON5 disease: A new case without neuropathologic evidence of brainstem tauopathy.
    Erro ME; Sabater L; Martínez L; Herrera M; Ostolaza A; García de Gurtubay I; Tuñón T; Graus F; Gelpi E
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31826985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical manifestations of the anti-IgLON5 disease.
    Gaig C; Graus F; Compta Y; Högl B; Bataller L; Brüggemann N; Giordana C; Heidbreder A; Kotschet K; Lewerenz J; Macher S; Martí MJ; Montojo T; Pérez-Pérez J; Puertas I; Seitz C; Simabukuro M; Téllez N; Wandinger KP; Iranzo A; Ercilla G; Sabater L; Santamaría J; Dalmau J
    Neurology; 2017 May; 88(18):1736-1743. PubMed ID: 28381508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microglial and Neuronal TDP-43 Pathology in Anti-IgLON5-Related Tauopathy.
    Cagnin A; Mariotto S; Fiorini M; Gaule M; Bonetto N; Tagliapietra M; Buratti E; Zanusso G; Ferrari S; Monaco S
    J Alzheimers Dis; 2017; 59(1):13-20. PubMed ID: 28550263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease.
    Gaig C; Ercilla G; Daura X; Ezquerra M; Fernández-Santiago R; Palou E; Sabater L; Höftberger R; Heidbreder A; Högl B; Iranzo A; Santamaria J; Dalmau J; Graus F
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Intrathecal B and Plasma Cells in Patients With Anti-IgLON5 Disease: A Case Series.
    Strippel C; Heidbreder A; Schulte-Mecklenbeck A; Korn L; Warnecke T; Melzer N; Wiendl H; Pawlowski M; Gross CC; Kovac S
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35031586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IgLON5 disease with distinctive brain MRI findings responding to immunotherapy: A case report.
    Pi Y; Zhang LL; Li JC
    Medicine (Baltimore); 2021 Jan; 100(4):e24384. PubMed ID: 33530233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA dependency and possible clinical relevance of intrathecally synthesized anti-IgLON5 IgG4 in anti-IgLON5 disease.
    Koneczny I; Macher S; Hutterer M; Seifert-Held T; Berger-Sieczkowski E; Blaabjerg M; Breu M; Dreyhaupt J; Dutra LA; Erdler M; Fae I; Fischer G; Frommlet F; Heidbreder A; Högl B; Klose V; Klotz S; Liendl H; Nissen MS; Rahimi J; Reinecke R; Ricken G; Stefani A; Süße M; Teive HAG; Weis S; Berger T; Sabater L; Gaig C; Lewerenz J; Höftberger R
    Front Immunol; 2024; 15():1376456. PubMed ID: 38827736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.